Kymera Therapeutics (NASDAQ:KYMR) Price Target Raised to $49.00

Kymera Therapeutics (NASDAQ:KYMR) had its price objective increased by Morgan Stanley from $45.00 to $49.00 in a research report report published on Wednesday morning,Benzinga reports. The brokerage currently has an equal weight rating on the stock.

A number of other brokerages have also recently weighed in on KYMR. Guggenheim raised their price objective on shares of Kymera Therapeutics from $45.00 to $52.00 and gave the stock a “buy” rating in a research note on Friday, November 1st. Leerink Partners reissued an “outperform” rating and issued a $60.00 price target on shares of Kymera Therapeutics in a report on Monday, September 9th. B. Riley increased their price objective on Kymera Therapeutics from $31.00 to $36.00 and gave the company a “neutral” rating in a research note on Tuesday, July 9th. Truist Financial reissued a “buy” rating and set a $53.00 price objective (down previously from $54.00) on shares of Kymera Therapeutics in a research note on Friday, November 1st. Finally, Leerink Partnrs upgraded Kymera Therapeutics to a “strong-buy” rating in a report on Monday, September 9th. Four analysts have rated the stock with a hold rating, ten have issued a buy rating and one has assigned a strong buy rating to the company’s stock. According to MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average target price of $51.21.

Kymera Therapeutics Trading Up 2.2 %

Shares of NASDAQ:KYMR traded up $1.09 on Wednesday, reaching $50.95. 300,187 shares of the company were exchanged, compared to its average volume of 368,128. The company has a 50-day moving average of $47.06 and a 200-day moving average of $41.16. The firm has a market cap of $3.30 billion, a price-to-earnings ratio of -21.77 and a beta of 2.21. Kymera Therapeutics has a 1-year low of $13.85 and a 1-year high of $53.27.

Kymera Therapeutics (NASDAQ:KYMR) last issued its quarterly earnings data on Thursday, October 31st. The company reported ($0.82) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.83) by $0.01. The firm had revenue of $3.74 million during the quarter, compared to analysts’ expectations of $10.34 million. Kymera Therapeutics had a negative return on equity of 24.96% and a negative net margin of 191.26%. Kymera Therapeutics’s revenue was down 20.9% on a year-over-year basis. During the same period in the previous year, the firm posted ($0.90) earnings per share. As a group, analysts forecast that Kymera Therapeutics will post -2.79 earnings per share for the current year.

Insiders Place Their Bets

In related news, Director Pamela Esposito sold 13,500 shares of Kymera Therapeutics stock in a transaction on Tuesday, September 17th. The shares were sold at an average price of $48.28, for a total transaction of $651,780.00. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. In other news, Director Jeffrey W. Albers sold 5,000 shares of the business’s stock in a transaction on Monday, August 26th. The shares were sold at an average price of $49.10, for a total transaction of $245,500.00. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink. Also, Director Pamela Esposito sold 13,500 shares of the firm’s stock in a transaction on Tuesday, September 17th. The shares were sold at an average price of $48.28, for a total transaction of $651,780.00. The disclosure for this sale can be found here. 15.82% of the stock is owned by insiders.

Institutional Trading of Kymera Therapeutics

Several large investors have recently modified their holdings of the business. Mirae Asset Global Investments Co. Ltd. raised its position in shares of Kymera Therapeutics by 6.7% in the 1st quarter. Mirae Asset Global Investments Co. Ltd. now owns 24,471 shares of the company’s stock valued at $984,000 after purchasing an additional 1,531 shares in the last quarter. Nvwm LLC bought a new position in Kymera Therapeutics during the 1st quarter valued at $294,000. Swiss National Bank grew its holdings in Kymera Therapeutics by 12.3% during the 1st quarter. Swiss National Bank now owns 79,700 shares of the company’s stock worth $3,204,000 after acquiring an additional 8,700 shares in the last quarter. Susquehanna Fundamental Investments LLC bought a new stake in shares of Kymera Therapeutics in the 1st quarter worth about $2,874,000. Finally, Keudell Morrison Wealth Management acquired a new stake in shares of Kymera Therapeutics in the 1st quarter valued at about $266,000.

Kymera Therapeutics Company Profile

Kymera Therapeutics, Inc, a biopharmaceutical company, focuses on discovering and developing novel small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body's own natural protein degradation system. It engages in developing IRAK4 program, which is in Phase II clinical trial for the treatment of immunology-inflammation diseases, including hidradenitis suppurativa, atopic dermatitis; STAT3 program for the treatment of hematologic malignancies and solid tumors, as well as autoimmune diseases and fibrosis; and MDM2 program to treat hematological malignancies and solid tumors.